MedTrace Logo

A Pharmacogenomics Study of Simvastatin-Induced Adverse Drug Reaction

NCT03261908 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2200

Last updated 2018-05-22

No results posted yet for this study

Summary

Adverse reactions of simvastatin are mostly slight and transient, however, the incidence of simvastatin-induced hepatic impairment and myopathy are obviously higher in Chinese population than other racial groups. There is still lack of research data in Chinese. In this study, we will investigate whether there are specific genotypes which may predict the incidence of simvastatin-induced hepatic impairment and myopathy in Chinese so as to provide a basis for developing guidelines on precise medication in simvastatin therapy apply to Chinese population.

Conditions

  • Simvastatin Adverse Reaction
  • Pharmacogenomics
  • Accurate Medication

Interventions

GENETIC

detection of genotype

detection of genotype by next generation sequencing

Sponsors & Collaborators

  • Cui Yimin

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03261908 on ClinicalTrials.gov